CII
GEVA

CR Intrinsic Investors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

CR Intrinsic Investors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,000
Closed -$633K – 443
2013
Q3 		$633K Sell
10,000
-108,161
-92% -$5.32M 0.02% 328
2013
Q2 		$4.96M Buy
+118,161
New +$5.38M 0.17% 182

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

CR Intrinsic Investors's GEVA Position: Q4 2013 in Review

CR Intrinsic Investors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2013, closing a stake of 10,000 shares — an estimated $633K sold.

CR Intrinsic Investors first reported a position in GEVA in Q2 2013 and held it in 2 quarters. The position peaked at $4.96M in Q2 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • CR Intrinsic Investors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 10,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2013, an estimated $633K.
  • CR Intrinsic Investors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 2 quarters.
  • CR Intrinsic Investors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $4.96M in Q2 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.